Clinical trials: Solid Tumors Harboring NTRK Fusion, open to volunteers
Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion cancer.
- Trial name
- NCT04945330
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Solid Tumors Harboring NTRK Fusion, NTRK
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
The goal of this clinical trial is to learn about the safety of drug CG001419. It also learn if drug CG001419 works to treat in locally advanced/metastatic adult solid tumours with NTRK gene fusions, NTRK gene point mutations…
- Conditions
- Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
- Trial name
- NCT07394374
- Testing
- CG001419 tablets
- Where
- 6 sites in China
- Volunteers
- 42 people
- Sponsor
- Cullgen (Shanghai),Inc
Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
- Trial name
- NCT05745623
- Testing
- ICP-723
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.